Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
about
How does adenosine control neuronal dysfunction and neurodegeneration?Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.Purinergic Signalling: Therapeutic Developments.Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease.Biochemical and Pharmacological Role of A1 Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy.The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease
P2860
Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Expression, pharmacology and f ...... odels of Huntington's disease.
@en
Expression, pharmacology and f ...... odels of Huntington's disease.
@nl
type
label
Expression, pharmacology and f ...... odels of Huntington's disease.
@en
Expression, pharmacology and f ...... odels of Huntington's disease.
@nl
prefLabel
Expression, pharmacology and f ...... odels of Huntington's disease.
@en
Expression, pharmacology and f ...... odels of Huntington's disease.
@nl
P2093
P50
P1476
Expression, pharmacology and f ...... odels of Huntington's disease.
@en
P2093
Fabrizio Vincenzi
Katia Varani
Maria Teresa Tebano
Patrizia Popoli
Rita Pepponi
Sarah Beggiato
P304
P356
10.1016/J.NBD.2014.08.013
P577
2014-08-15T00:00:00Z